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Abstract 
Mycetoma or ‘Madura foot’ is a chronic infection of skin and subcutaneous tissues, fascia and bone. It may be caused by true fungi 
(eumycetoma) or by filamentous bacteria (actinomycetoma). The lesions are composed of suppurating abscesses and draining sinuses 
with the presence of grains which are characteristic of the etiologic agents. The introduction of new broad spectrum antimicrobials and 
antifungals offers the hope of improved drug efficacy. This article discusses the historical aspects, epidemiology, clinical findings, 
laboratory diagnosis and treatment of mycetoma. 
 
Streszczenie 
Mycetoma lub ‘stopa madurska’ to przewlekłe zakaŜenie skóry i tkanki podskórnej, powięzi i kości. MoŜe być spowodowane przez 
grzyby prawdziwe (eumycetoma) lub bakterie nitkowate (actinomycetoma). Zmiany przedstawiają się jako ropiejące wrzody i zatoki z 
obecnością  ziaren,  które  są  charakterystyczne  dla  tych  czynników  etiologicznych.  Wprowadzenie  nowych  o  szerokim  spektrum 
antybiotyków  i  leków  przeciwgrzybiczych  daje  nadzieję  na  poprawę  skuteczności  leczenia.  W  tym  artykule  omówiono  aspekty 
historyczne, epidemiologię, objawy kliniczne, diagnostykę laboratoryjną i leczeniu mycetoma. 
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Introduction 
Mycetoma  is  a  localized  chronic,  suppurative 
and  deforming  granulomatous  infectious  disease  of 
subcutaneous  tissue,  skin  and  bones,  that  is  present 
worldwide  and  is  endemic  in  tropical  and  subtropical 
regions. Mycetoma is a pathological process in which the 
causative agents – a fungus (eumycetoma) or a bacterium 
(actinomycetoma)  from  an  exogenous  source  produce 
grains.  Since  the  treatment  of  these  two  etiologies  is 
entirely  different,  a  definite  diagnosis  after 
histopathological  and  microbiolological  examination  is 
mandatory. The disease is notoriously difficult to treat. 
Treatment  consists  of  long  courses  of  antifungals  and 
antibacterials often combined with surgery. 
 
Historical aspects 
Gill, who worked at a dispensary in the southern 
province  of  Madura,  first  recognized  mycetoma  as  a 
disease entity in 1842 [1]. The condition had been known 
there for many years. Godfrey first documented a case of 
mycetoma  in  Madras,  India.  Native  people  of  the 
province commonly called the disease as ‘Madura foot’. 
It was Vandyke Carter, who studied the condition over a 
period  of  of  several  years  from  1860-1874  and 
established  the  fungal  etiology  of  this  disorder.  He 
proposed the term ‘Mycetoma’, literally meaning fungal 
tumor  for  the  condition,  since  he  found  it  could  also 
effect  other  parts  of  the  body  than  the  foot  [1].  He 
classified his cases by the colour of the grains found in 
the sinus tracts as pale or white, black or red. Pinoy in 
1913 recognized the possibility of classifying the cases 
of mycetoma by grouping the causative organisms, and 
in 1916 Chalmers and Archibald reviewed the reported 
cases and published such a classification dividing them 
into two groups [2,3]: 
Group  1  -  Maduramycosis,  caused  by  true  fungi 
exhibiting septate filaments usually with chlamydospores 
and; 
Group 2 - Actinomycosis, caused by delicate non-septate 
filaments  of  the  Actinomyces  which  belong  to  higher 
bacteria. 
 
Epidemiology 
Mycetomas  are  mainly  but  not  exclusively 
found  in  the  dry  tropics  where  there  is  a  low  annual 
rainfall.  It  is  a  disease  of  poverty,  most  commonly 
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affecting  agricultural  workers  and  people  who  are 
habitually barefoot.  The species causing mycetoma vary 
from country to country and agents that are commoner in 
one  region,  are  rarely  seen  in  others.  Actinomycete 
Streptomyces  somaliensis  is  isolated  most  often  from 
from  patients  originating  from  Sudan  and  the  Middle 
East.  In  India,  actinomycotic  mycetoma  is  more 
commonly  encountered  than  eumycotic  mycetoma  [4]
. 
However, eumycotic mycetoma accounts for the majority 
of cases reported from the northern region [5].  
Men are more commonly affected than the women and 
the maximal incidence is seen in the age group of 21-40 
years.  Since  it  mostly  affects  young  men,  it  has  a 
socioeconomic effect on the dependent family members. 
 
Pathogenesis 
The  disease  is  usually  acquired  while 
performing  agricultural  work.  The  organisms  are 
implanted  subcutaneously,  usually  after  a  penetrating 
injury. It is usual to find any underlying predisposition in 
patients  with  mycetoma,  and  the  persistence  of  the 
organism after an initial inoculation appears to be related 
to its ability to evade host defenses through a variety of 
adaptations  such  as  cell  wall  thickening  and  melanin 
production. 
 
Etiology 
Mycetomas may be caused by various species of 
fungi and bacteria, which occur as saprophytes in soil or 
on  the  plants.  Actinomycotic  mycetoma  is  caused  by 
aerobic species of actinomycetes belonging to the genera 
Nocardia, Streptomyces and Actinomadura. 
Eumycotic  mycetoma  is  associated  with  a  variety  of 
fungi, the most common being Madurella mycetomatis, 
Pseudoallescheria boydii and Acremonium species. 
 
Common causative agents of actinomycotic mycetoma: 
Agent                                                Grain colour 
Nocardia asteroids                             White 
Nocardia brasilienses                         White 
Nocardia otitidiscaviarum                 White 
Actinomadura madurae                     White 
Actinomadura pelletieri                     Red to pink 
Streptomyces somaliensis                  White-to-yellow 
 
Common causative agents of eumycotic mycetoma:- 
Agent                                             Grain colour 
Madurella mycetomatis                 Black to brown 
Madurella grisea                            Black to brown 
Leptosphaeria senegalensis           Black       
Curvularia lunata                           Black 
Neotestidina rosatii                       Yellow 
Acremonium spp.                          White to yellow 
Fusarium spp.                                White to pale yellow 
Scedosporium apiospermium        White to pale yellow 
 
Clinical presentation of the disease 
Mycetoma is a chronic suppurative infection of 
the  subcutaneous  tissue  and  contagious  bone.  The 
clinical  features  are  fairly  uniform,  regardless  of  the 
organism involved [6,7]
. Since trauma favours infection, 
feet are the most common site for infection and account 
for  almost  two-thirds  of  cases.  Other  sites  include  the 
lower leg, hands, head, neck, chest, shoulder and arms. 
Most cases start out as a small, painless, subcutaneous 
nodule at the site of injury. The nodule over a period of 
time  begins  to  soften  on  the  surface  and  ulcerates  to 
discharge  a  viscous,  purulent,  seropurulent  or 
serosanguinous  fluid  containing  characteristic  granules. 
The  granules  vary  in  size,  colour  and  consistency 
depending on the etiological species. These grains are the 
hallmark of mycetoma. 
With  time papules, pustules and nodules appear which 
also break down to form draining sinuses appearing on 
the skin surface. The disease progresses to involve the 
surrounding  tissues  which  become  swollen,  indurated 
and  deformed  by  fibrous  tissue  reaction  and  multiple 
sinus  formation.  The  condition  is  usually  painless,  but 
become very painfull with the involvement of bones or 
as a result of secondary bacterial infection. 
Mycetoma is usually localized but may extend slowly by 
direct  contiguity  along  the  fascial  planes,  invading  the 
subcutaneous tissue, fat, ligaments, muscles, and bones. 
In eumycotic mycetoma, there may be multiple punched 
out  lytic  lesions  in  bones.  Actinomycotic  mycetoma  is 
characterized  by  both  osteolytic  and  osteosclerotic 
lesions. The end result is gross swelling of the affected 
foot or other part with serious deformity. 
 
Complications 
The  disease  causes  disfigurement  but is rarely 
fatal.  In  advances  cases,  deformities  or  ankylosis  may 
occur.  Chronic  neglected  infection  may  necessitate 
amputation. Immunocompromised patients may develop 
invasive  infection.  Lymphatic  obstruction  and  fibrosis 
may cause lymphoedema. Complications may also result 
from  toxicity  due  to  prolonged  antimicrobial  or 
antifungal therapy. 
 
Differential Diagnosis 
Mycetoma  has  to  be  differentiated  from  the 
following: 
·  Osteomyelitis (bacterial or tubercular) 
·  Actinomycosis 
·  Botryomycosis 
·  Chromoblastomycosis 
·  Sporotrichosis 
·  Atypical mycobacterial infection 
 
Laboratory Diagnosis 
Clinical material: 
Serosanguinous  fluid  or  seropurulent  fluid, 
scrapings  of  sinuses,  tissue  biopsy  or  excised  sinus 
should  be  examined  for  the  presence  of  grains.  Saline 
dressings applied overnight over the swelling can also be 
observed  for  the  presence  of  grains.  The  grains 
discharged  from  the  sinuses  vary  in  size,  colour  and 
consistency,  features  used  for  the  rapid  provisional 
identification of the etiological agent [8,9]. 
 
Direct microscopy: 
A  Gram  stain  is  of  considerable  value  in 
distinguishing  between  actinomycetoma  and 
eumycetoma. The fine branching filaments, only about 1 
micron  thick,  within  the  grains  of  actinomycetoma  are 
gram-positve.  The  grains  of  eumycetoma  are  gram 
negative [10,11]. The filaments and hyphae of the causal 
agent can be stained better in biopsy samples with Gram 
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stain (actinomycetoma) or Gomori methamine silver or 
periodic-acid-Schiff stains (eumycetoma). 
The  study  of  discharged  granules  crushed  on  the slide 
and  stained  with  lactophenol  blue  particularly  allows 
differentiation  between  the  thin  filaments  of 
actinomycetoma and the thicker hyphae of eumycetoma. 
Hence,  these  special  stains  are  of  value  in  further 
confirming the the nature of the organism. 
 
Histology: 
Histological sections stained with H & E stain 
show  suppurative  granulomas  (composed  of 
neutrophills),  surrounding  characteristic  grains  in  the 
subcutaneous  tissue.  Neutrophillic  infiltrate  is 
surrounded  by  palisading  histiocytes  beyond  which  a 
mixed  inflammatory  infiltrate  comprising  of 
lymphocytes,  plasma  cells,  eosinophills,  macrophages 
and fibrosis was seen with multinucleated gaint cells.  
In  case  of  Actinomycotic  mycetoma,  the 
actinomycetoma  grain  is  surrounded  by  homogenous 
eosinophillic  material  (Splendore-Hoeppli  reaction).  In 
cases  of  eumycotic  mycetoma,  thick  club-shaped 
structures (chlamydospores) are seen. 
 
Culture: 
Grains  of  many  species  have  overlapping 
morphological features and therefore culture is required 
for  an  accurate  identification  of  the  causative  agent. 
Clinical  specimens  should  be  inoculated  into  primary 
isolation media, like Sabouraud’s dextrose agar. 
 
Serology: 
Serolological  tests  are  not  available  routinely. 
However, they are gaining importance as highly usefull 
diagnostic procedures in the early stages of the disease, 
before the granules are formed. ELISA appears to be a 
sensitive test for the detection of antibodies in mycetoma 
infections, especially in epidemiological work [12]. 
 
Advanced diagnostic techniques: 
Modern  molecular  techniques  have  been 
developed,  including  rapid  and  inexpensive  species-
specific  PCR  analysis,  which  have  permitted 
identification  of  new  species  and  phylogenetic 
relationships [13-15]. 
 
Imaging techniques 
Radiology  and  ultrasonography  enable 
assessment  of  disease  extent  and  bony  involvement  if 
any [16]. The use of helical computed tomography has 
recently been shown to provide detailed assessments of 
soft  tissue  and  visceral  involvement  [17].  Magnetic 
resonance  imaging  (MRI)  provides  the  most 
comprehensive method for assessment of the bone and 
soft  tissue  involvement  and  may  also  be  useful  in 
evaluating  the  differential  diagnosis  of  the  swelling 
[18,19]. 
 
Treatment 
The choice of treatment for mycetoma depends 
on the causative organism which has been identified on 
the  basis  of  morphology  of  grain  in  histopathology 
sections. 
Actinomycetomas  are  usually  amenable  to  antibiotic  
treatment. In the treatment of actinomycotic mycetoma, 
sulphonamides,  rifampicin,  tetracyclines,  isoniazid, 
streptomycin,  amikacin  and  amoxicillin-clavulanic  acid 
have  been  used  with  variable  results  [20-22].  The 
addition  of  aminoglycosides  and  cotrimoxazole  gives 
higher efficacy, and is associated with shorter treatment 
duration.  Parenteral  amikacin  and  oral  cotrimoxazole 
combination is especially advocated for use in cases at 
risk  of  pulmonary  spread  or  vertebral  involvement 
[21,22].  Cure  rates  vary  widely,  ranging  from  60%  to 
90%.  Combined  treatment  is  preferred  to  prevent  the 
development  of  drug  resistance  and  to  eradicate  any 
residual infection [23]. 
Eumycotic mycetomas usually respond less well to drug 
therapy  and  are  therefore  managed  by  long  courses  of 
antifungals, combined with aggressive surgical excision 
or  debulking  of  the  lesions.  Thus  complete  surgical 
excision of the lesion and post surgical medical therapy 
should form the first line of management in eumycotic 
mycetoma.  Griseofulvin,  amphotericin  and  terbinafine 
have  shown  a  limited  or  poor  response  [24,25]
. 
Fluconazole  has  not  been  found  to  be  effective  but 
ketoconazole and itraconazole have both been shown to 
have  a  good  efficacy  [26,27].  Itraconazole  and 
terbinafine  are  presently  the  major  antifungal  agents 
considered for the medical management of eumycetoma 
[28].  Newer  broad-spectrum  triazoles,  such  as 
Voriconazole  and  Posaconazole  have  been  reported  to 
have promising results for patients of eumycetoma which 
is refractory to standard therapies [29,30]. However their 
high  costs  are  prohibitive  for  use  in  moost  endemic 
regions. 
 
Conclusion 
Since  mycetoma  is  a  relatively  painless 
condition,  it  is  often  diagnosed  at  an  advanced  stage. 
There is a high incidence of secondary bacterial infection 
in mycetoma lesions. This can cause increased pain and 
disability  as  well  as  septicemia  which  may  be  fatal  if 
untreated.  This  emphasizes  the  need  for  its  correct 
diagnosis after meticulous clinical examination, assisted 
by  histological  and  microbiological  studies  along  with 
the use of special stains and a proper treatment. 
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